DiBiase Mary's Insider Trades & SAST Disclosures
DiBiase Mary's most recent trade in X4 Pharmaceuticals Inc was a trade of 650,000 Common Stock done . Disclosure was reported to the exchange on Feb. 12, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern DiBiase Mary.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 650,000 | 1,140,980 (7%) | 4% | 0 | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 61,178 | 513,238 (3%) | 0% | 0 | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 22,258 | 490,980 (3%) | 0% | 0.5 | 10,094 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 230,645 | 519,755 (3%) | 1% | 0 | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 04 Oct 2024 | 67,695 | 452,060 (2%) | 0% | 0.6 | 38,329 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 09 Sep 2024 | 2,642 | 289,110 (1%) | 0% | 0.7 | 1,738 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 11 Mar 2024 | 15,409 | 291,752 (1%) | 0% | 0.9 | 13,591 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 428,248 | 428,248 | - | - | Stock Appreciation Right | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
DiBiase Mary | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 12 Feb 2024 | 3,683 | 307,161 (1%) | 0% | 1.0 | 3,709 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.89 per share. | 30 Jun 2023 | 464 | 150,536 (0%) | 0% | 1.9 | 877 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 23 Jun 2023 | 857 | 151,000 (0%) | 0% | 1.9 | 1,654 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 15 Jun 2023 | 857 | 151,857 (0%) | 0% | 2.2 | 1,911 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 10 Mar 2023 | 18,192 | 152,714 (0%) | 0% | 0.8 | 15,281 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Feb 2023 | 4,348 | 170,906 (1%) | 0% | 0.9 | 4,044 | Common Stock |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2022 | 1,350,000 | 1,350,000 | - | - | Stock Appreciation Right | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Aug 2022 | 1,713 | 177,896 (1%) | 0% | - | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Jun 2022 | 1,578 | 179,609 (1%) | 0% | - | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Jun 2022 | 856 | 181,187 (1%) | 0% | - | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2022 | 856 | 182,043 (1%) | 0% | - | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 105,000 | 182,899 (1%) | 0% | 0 | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 12,545 | 77,899 (0%) | 0% | - | Common Stock | |
|
X4 Pharmaceuticals Inc
Board Meeting 5-year low High Loss High Volume |
Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2021 | 27,000 | 90,444 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges